Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal CD19/BCMA CAR T-cells in Relapsed/Refractory SLE
NCT06920433Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Zhejiang University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 90 days and 1 more. Started Apr 2025; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06920433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920433.